Clinical trial

DP303c in Patients With HER2-positive Advanced Breast Cancer

NCT05901935

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-07-01

PhasePHASE3

Study timeline

Study start (estimated)2023-07-01Date precision: month

Registry last updated2023-06-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Advanced Breast Cancerunresolved

Interventions

DP303cDRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Vinorelbine TartrateDRUG · verified · RxNorm: vinorelbine tartrate

Capecitabine tabletsDRUG

Sponsors & collaborators

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05901935 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.